Methylphenidate
Brain Hypoxia - Ischemia
Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Massachusetts General Hospital
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03814356CT.gov Stimulant Therapy Targeted to Individualized Connectivity Maps to Promote ReACTivation of Consciousness | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Brain Hypoxia - Ischemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Methylphenidate (this asset) | Massachusetts General Hospital | P1 | CC · 43 |
| Lacosamide | University of North Carolina, Chapel Hill | P4 | BB |
| Valproic Acid | University of North Carolina, Chapel Hill | P4 | BB |
| Fosphenytoin | University of North Carolina, Chapel Hill | P4 | B |
| Autologous Umbilical Cord Blood | Michael Cotten | P2 | CCC |
| Phenobarbital | University of North Carolina, Chapel Hill | P4 | CCC |
| Baclofen | University Hospital, Bordeaux | P2 | CCC |
| Oxygen | Capital Medical University | N/A | D |
| Indocyanine Green | University of Pennsylvania | Unk | D |
+2 more in the Brain Hypoxia - Ischemia cohort
Other indications for Methylphenidate
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Attention Deficit-Hyperactivity Disorder | — | P4 | BBB · 76 |
| Multiple Sclerosis | — | P3 | BB · 70 |
| Alzheimer Disease | — | P4 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Methylphenidate in Brain Hypoxia - Ischemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/methylphenidate-brain-hypoxia-ischemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →